These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20157125)

  • 1. ACP Journal Club. Pioglitazone was associated with lower risk for adverse cardiovascular events than rosiglitazone in older patients.
    Basu A
    Ann Intern Med; 2010 Feb; 152(4):JC-213. PubMed ID: 20157125
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone.
    Wang AT; Smith SA
    Ann Intern Med; 2010 Dec; 153(12):JC6-11. PubMed ID: 21173400
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Review: rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes.
    Deedwania P
    Ann Intern Med; 2011 Aug; 155(4):JC2-12. PubMed ID: 21844545
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
    Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP Journal Club. Testosterone increased risk for adverse events in older men with mobility limitations.
    Lichtenstein MJ
    Ann Intern Med; 2010 Dec; 153(12):JC6-7. PubMed ID: 21173408
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users.
    Brophy JM
    Ann Intern Med; 2011 Oct; 155(8):JC4-5. PubMed ID: 22007064
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Oct; 151(8):JC4-8. PubMed ID: 19841445
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
    Gegick CG; Altheimer MD
    Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
    Jain R; Mullins CD; Lee H; Wong W
    Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACP Journal Club. Review: Preoperative brain natriuretic peptide level is an independent predictor of adverse cardiovascular events after noncardiac surgery.
    Kaw R; Cai O
    Ann Intern Med; 2010 Mar; 152(6):JC3-12. PubMed ID: 20231554
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Review: lithium is associated with adverse events in patients with mood disorders.
    Preda A
    Ann Intern Med; 2012 Jul; 157(2):JC2-10. PubMed ID: 22801701
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP journal club. Cognitive-behavioral therapy reduced risk for recurrence in patients recently hospitalized with cardiovascular disease events.
    Thase ME
    Ann Intern Med; 2011 May; 154(10):JC5-04. PubMed ID: 21576522
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients.
    Sanyal AJ
    Ann Intern Med; 2010 Sep; 153(6):JC3-12. PubMed ID: 20855789
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACP Journal Club. Review: Statins reduce mortality and cardiovascular events in adults at risk for cardiovascular disease.
    Davidson RA; Rosenberg E
    Ann Intern Med; 2009 Oct; 151(8):JC4-14. PubMed ID: 19841451
    [No Abstract]   [Full Text] [Related]  

  • 19. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.